ArticleBiology direct2026
miR-196b inhibits tumor proliferation and metastasis by targeting GATA6 in endometrial cancer.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEndometrial cancer (EC) is a common gynecological malignancy with increasing incidence, yet its precise pathogenesis remains unclear. MicroRNAs (miRNAs) have been widely implicated in tumorigenesis. Although studies suggest that miR-196b is closely associated with the progression of various malignancies, its specific biological functions and mechanisms in EC remain to be elucidated.
resultsIn this study, analysis of tissue and serum samples from EC patients revealed that miR-196b is downregulated in EC, whereas GATA6 is upregulated, with a notable negative correlation between their expression levels. In Ishikawa and HEC-1 A EC cell lines, functional assays including CCK-8, colony formation, wound healing, and Transwell experiments revealed that downregulation of miR-196b significantly enhanced cell proliferation, migration, and invasion. A nude mouse xenograft model further confirmed that high miR-196b expression weakened the tumorigenic ability of EC cells. Mechanistically, dual-luciferase reporter assays identified GATA6 as a direct target of miR-196b. Downregulation of miR-196b facilitated the proliferation, metastasis, and epithelial-mesenchymal transition (EMT) of EC cells by up-regulating GATA6. The miR-196b/GATA6 axis is involved in regulating the activity of the AKT/ERK signaling pathway. Furthermore, through a series of bioinformatics analyses, we found that miR-196b and GATA6 have potential as diagnostic and prognostic markers for EC.
conclusionsThis study elucidates the molecular mechanism by which miR-196b suppresses EC progression by targeting GATA6. These findings provide novel insights into the pathogenesis of EC and highlight the potential of miR-196b/GATA6 as a diagnostic and prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.